In January 2026, Century Therapeutics completed an oversubscribed $135 million private placement, led by TCGX with participation from RA Capital Management, Commodore Capital and others. This financing extends the company's cash runway into the first quarter of 2029, strengthening its balance sheet for ongoing pipeline development.

Century is advancing its lead program, CNTY-813, through IND-enabling studies, achieving compelling preclinical results including maintenance of normoglycemia in animal models for over six months and completion of a GMP master cell bank. The company plans to submit an IND for this beta islet replacement therapy in Q4 2026 with initial clinical data anticipated in H2 2027.

The CD19-targeted CAR-iT therapy CNTY-308, engineered with Allo-Evasion™ 5.0, has demonstrated functional comparability to primary CAR-T cells in preclinical studies and is projected to enter clinical trials in 2026, pending completion of IND-enabling activities and regulatory clearance.

Preliminary clinical data from the CARAMEL investigator-sponsored trial of CNTY-101 in autoimmune diseases are expected in 2026, following earlier reports of good tolerability and early signs of clinical response, which could inform further development strategies.